Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation: a useful complement to stroke risk stratification schema. - Suppr | 超能文献

Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation: a useful complement to stroke risk stratification schema.

作者信息

Kakar Puneet, Lane Deirdre, Lip Gregory Y H

出版信息

Chest. 2006 Nov;130(5):1296-9. doi: 10.1378/chest.130.5.1296.

DOI:10.1378/chest.130.5.1296

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation: a useful complement to stroke risk stratification schema.

Chest. 2006 Nov;130(5):1296-9. doi: 10.1378/chest.130.5.1296.

2

Development of a contemporary bleeding risk model for elderly warfarin recipients.老年华法林使用者当代出血风险模型的开发。

Chest. 2006 Nov;130(5):1390-6. doi: 10.1378/chest.130.5.1390.

3

Discontinuation of anticoagulation therapy in patients who have experienced an acute intramuscular bleed and are also at risk for a stroke.对于经历过急性肌肉内出血且有中风风险的患者，停止抗凝治疗。

Am J Phys Med Rehabil. 2014 Oct;93(10):925-6. doi: 10.1097/PHM.0b013e3182922bcb.

4

Bleeding risk on warfarin among elderly patients with atrial fibrillation.老年房颤患者服用华法林后的出血风险

J Am Coll Cardiol. 2010 Mar 2;55(9):932; author reply 932-3. doi: 10.1016/j.jacc.2009.11.037.

5

Risk of anticoagulation for atrial fibrillation in the elderly.老年人房颤抗凝治疗的风险

Am J Geriatr Cardiol. 2007 Sep-Oct;16(5):325-6. doi: 10.1111/j.1076-7460.2007.06207.x.

6

Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA DS VASc 1 or 2): A treatment dilemma.非瓣膜性心房颤动且伴有 1 个非性别相关危险因素（CHA2DS2-VASc 评分为 1 或 2）患者的华法林处方：一个治疗困境。

Cardiovasc Ther. 2018 Feb;36(1). doi: 10.1111/1755-5922.12310. Epub 2017 Nov 11.

7

Relationship of Age With Stroke and Death in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: AMADEUS Trial.非瓣膜性心房颤动抗凝患者年龄与中风及死亡的关系：AMADEUS试验

Stroke. 2015 Nov;46(11):3202-7. doi: 10.1161/STROKEAHA.115.010614. Epub 2015 Oct 13.

8

Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.新型房颤抗凝出血风险评分对预测抗凝出血风险的比较验证：HAS-BLED（高血压、肾功能/肝功能异常、卒中、出血史或倾向、INR 易变、高龄、同时使用药物/酒精）评分。

J Am Coll Cardiol. 2011 Jan 11;57(2):173-80. doi: 10.1016/j.jacc.2010.09.024. Epub 2010 Nov 24.

9

Bleeding risk factors affecting warfarin therapy in the elderly with atrial fibrillation.影响老年房颤患者华法林治疗的出血风险因素。

Dimens Crit Care Nurs. 2014 Mar-Apr;33(2):57-63. doi: 10.1097/DCC.0000000000000022.

10

Atrial fibrillation: stroke prevention in older adults.心房颤动：老年人的卒中预防。

Clin Geriatr Med. 2012 Nov;28(4):617-34. doi: 10.1016/j.cger.2012.08.003.

引用本文的文献

1

A review of the safety of anticoagulants in older people using the medicines management pathway: weighing the benefits against the risks.老年人使用药物管理途径的抗凝剂安全性综述：权衡利弊。

Ther Adv Drug Saf. 2011 Apr;2(2):45-58. doi: 10.1177/2042098611400495.

2

Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician.人工心脏瓣膜患者的抗血栓治疗：为临床医生翻译的指南。

J Thromb Thrombolysis. 2011 May;31(4):514-22. doi: 10.1007/s11239-011-0574-9.

3

Antithrombotic treatment in atrial fibrillation.心房颤动的抗栓治疗

Heart. 2007 Jan;93(1):39-44. doi: 10.1136/hrt.2006.099911. Epub 2006 Sep 4.